Business Wire

MA-HOLOGIC

27.2.2024 14:02:00 CET | Business Wire | Press release

Share
Hologic to Unveil Groundbreaking AI Research at ECR 2024

Hologic, Inc. (Nasdaq: HOLX) continues to deliver on its commitment to advancing women’s health by unveiling new research in artificial intelligence (AI) and offering innovative educational opportunities at the annual European Congress of Radiology (ECR) in Vienna, Austria from February 28 to March 2.

The pioneer behind 3D mammography, Hologic will present new data that showcase how next-generation deep-learning solutions can assist with breast cancer detection and improve workflow for radiologists. Presented by esteemed breast imaging specialist and study author Dr. Sarah M. Friedewald, Associate Professor of Radiology and Chief of Breast Imaging at Northwestern Memorial Hospital, the research shows that Hologic’s Genius AI® Detection solution has an exceptional ability to correctly match pairs of Regions of Interest (ROIs) in different views.1

“These data reveal how AI can help us correlate ROIs in a way that we have never seen before, which underscores that deep-learning technology can supplement our workflow as radiologists and help us provide better patient care,” said Dr. Friedewald. “Beyond its impact on our daily practices, these data emphasize the transformative potential AI has to drive improvements across the breast health spectrum. I’m looking forward to sharing this information with my colleagues from around the globe at ECR.”

In addition, Dr. Friedewald will also present research highlighting how the Genius AI Detection algorithm can help radiologists identify potential cancers on mammograms previously interpreted as normal.2 In a third study, research will be presented that demonstrates Hologic’s deep learning-based AI algorithm can help significantly enhance performance, surpassing traditional machine learning Computer-Aided Detection (CAD) algorithms in specificity and overall effectiveness.3

“Research and education are central tenets of Hologic’s innovation, to support radiologists in achieving better patient outcomes,” said Tanja Brycker, Vice President, Strategic Development, Breast & Skeletal Health and Gynecological Surgical Solutions at Hologic. “We’re excited to present groundbreaking research at ECR and to continue our collaboration with Bayer on contrast-enhanced mammography. By offering our customers the opportunity to engage with world-renowned experts and explore our latest technology, we are ensuring they feel confident in their patient care procedures and decisions.”

Hologic and Bayer will co-sponsor a contrast-enhanced mammography (CEM) symposium, facilitated by globally recognized breast imaging radiologists Dr. Jacopo Nori, Chief of Breast Imaging at Careggi University Hospital in Florence, Italy, and Dr. Marc Lobbes, Chairperson of the Board, Department of Medical Imaging at Zuyderland Medical Center in Sittard-Geleen, the Netherlands.

The symposium, which will take place on Thursday, February 29 at 11 a.m. CET, is designed to provide radiologists with an understanding of how CEM can be effectively implemented into their daily practice.

Hologic’s Genius AI® Detection technology is a cutting-edge solution now commercially available in the U.S., with plans for rollout in Europe, Canada and Asia by the end of 2024.

About Hologic, Inc.

Hologic, Inc. is a global medical technology innovator focused on improving the health and well-being of women, their families and communities through early detection and treatment. Its advancements include invention of the world’s first commercial 3D mammography system to find breast cancer earlier; leadership in testing for cervical cancer, sexually transmitted infections and respiratory illnesses; and minimally invasive surgical technologies for uterine fibroids and abnormal uterine bleeding.

The company also champions women through the Hologic Global Women’s Health Index, which provides a science-backed data framework for improving women’s well-being.

Forward-Looking Statements

This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.

This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to womenshealth@hologic.com.

Hologic, The Science of Sure and Genius AI are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

Views and opinions expressed herein by third parties are theirs alone and do not necessarily reflect those of Hologic. Dr. Sarah M. Friedewald is a paid Hologic consultant.

Source: Hologic, Inc.

____________________

1

Correlating breast lesions in tomosynthesis CC and MLO views using artificial intelligence (AI). Authors: Sarah Friedewald (Northwestern), Chirag Phargi (Solis). Accepted as podium presentation.

2

Evaluating performance of an artificial intelligence (AI) detection system on prior screening tomosynthesis studies of breast cancer patients. Authors: Sarah Friedewald (Northwestern), Chirag Phargi (Solis). Accepted as podium presentation.

3

Performance of a traditional machine learning computer-aided detection (CADe) algorithm versus a deep learning artificial intelligence (AI) algorithm on digital breast tomosynthesis (DBT) studies. Authors: Manisha Bahl (MGH), Constance Lehman (MGH). Accepted as electronic poster.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240227246191/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press release

With Picsart Platform, developers can build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. Key Takeaways One bundle, four ways to build: the API, the CLI, a playground to test models, and Picsart Media Studio, an MCP server that works with compatible AI assistants. One integration for image, video, audio and text generation from 250+ models across 30+ providers, with the freedom to switch models as a product evolves. Self-serve users pay per generation at competitive, published rates. Developers get access to Picsart's proprietary editing models, like Enhance and background removal, which are only available on Picsart Platform. Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 mil

NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release

The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e

Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope20.11.2026 18:40:00 CET | Press release

Frontgrade processors and radiation-hardened microelectronics support critical spacecraft and instrument functions on NASA’s flagship astrophysics mission Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectronics, providing critical processing, communications, power-management and control functions across the spacecraft. At the centre of Roman’s computing architecture are Frontgrade Gaisler’s GR740 and GR712RC processors. The GR740 radiation-hardened quad-core LEON4FT processor serves as the computing engine for the Wildcat Processor Card, used in the spacecraft’s primary and redunda

Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 16:05:00 CET | Press release

On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con

ViTAA Medical and The Society for Vascular Surgery Announce Strategic Partnership20.11.2026 15:00:00 CET | Press release

ViTAA Medical to Become Key SVS AI Partner, Advancing AI Education and Responsible Adoption in Vascular Care ViTAA Medical Solutions Inc. (ViTAA) today announced a strategic partnership with The Society for Vascular Surgery (SVS) to advance evidence, education, and the responsible adoption of quantitative imaging and artificial intelligence in vascular care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120954362/en/ The partnership will support evidence building, best practices, educational resources for SVS members, physicians and trainees on AI validation, interpretation, and clinical limitations. The relationship has the potential to pave the way for additional AI tools and resources for SVS members through the Society in the future. The partnership creates a framework for the organizations to lead AI-enabled research opportunities involving imaging and clinical outcomes. Mitchel Benovoy, PhD, Chief Executive Officer

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye